Sugi Predict

Sugi Predict / Compounds / SCHEMBL2619228

SCHEMBL2619228

SCHEMBL2619228

Cc1c[nH]c2cnccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 11/20 0.56
▸ NFATC1 O95644 6/20 0.56
▸ GSK3B P49841 4/20 0.56
▸ CDK2 P24941 2/20 0.53
▸ DYRK1B Q9Y463 2/20 0.53
▸ ATM Q13315 1/20 0.52
▸ PIM1 P11309 2/20 0.51
▸ PIM3 Q86V86 1/20 0.51
▸ PIM2 Q9P1W9 1/20 0.51
▸ PDPK1 O15530 1/20 0.49
▸ TGFBR1 P36897 1/20 0.49
▸ IKBKE Q14164 1/20 0.49
▸ IGF1R P08069 1/20 0.46
▸ TDO2 P48775 2/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ GABRP O00591 1/20 0.42
▸ GABRD O14764 1/20 0.42
▸ IKBKB O14920 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29535106 0.83 ATM (0.52) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL3224448 0.83 ATM (0.52) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL1009087 0.75 DYRK1A (0.56) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL245511 0.75 DYRK1A (0.61) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL29814872 0.75 PIM1 (0.59) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL1892610 0.75 PIM1 (0.59) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL18746021 0.75 DYRK1A (0.56) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL19443754 0.75 DYRK1A (0.56) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL21917255 0.75 DYRK1A (0.66) DYRK1ANFATC1GSK3BCDK2DYRK1B
SCHEMBL3147182 0.75 DYRK1A (0.56) DYRK1ANFATC1GSK3BCDK2DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 — — WO disclosed
EP-3801499-B1 INHIBITORS OF SARM1 DISARM THERAPEUTICS INC (US) 2024-02-28 — — EP disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
EP-3555070-B1 AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF EPIZYME INC (US) 2023-08-09 — — EP disclosed
WO-2023133457-A1 NOVEL KALIRIN INHIBITORS FOR REGULATION OF SYNAPTIC PLASTICITY AND NEUROPATHIC PAIN TREATMENT NORTHWESTERN UNIVERSITY (US) 2023-07-13 — — WO disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 — — WO disclosed
WO-2023107723-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 — — WO disclosed
US-20220289739-A1 SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2022-09-15 — — US disclosed
US-7169795-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-01-30 — — US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 — — US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 — — US disclosed
WO-2004108892-A2 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-16 — — WO disclosed
WO-2004083174-A2 SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 — — WO disclosed
WO-2004041776-A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-21 — — WO disclosed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 — — WO disclosed
WO-2003047520-A2 SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 — — WO disclosed
WO-2003048081-A2 GLYCINAMIDES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 — — WO disclosed
WO-2003026652-A1 LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 DYRK1A 860/4885NFATC1 3336/4885GSK3B 537/4885
US-20220289739-A1 SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS TLR7, TLR1, TLR9 DYRK1A 3683/4885NFATC1 72/4885GSK3B 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.